Episode 22: Non Melanoma Skin Cancers - BCC and Merkle Cell Carcinoma

As the southern hemisphere basks in summer's beautiful warmth, Michael and Josh skip the beach to explore skin cancer. While melanoma usually takes centre stage in the oncological world, it is far less common than basal cell carcinoma or squamous cell carcinoma. Metastatic squamous cell carcinoma now has a viable and effective treatment option called cemiplimab. At the other end of the spectrum, Michael investigates the very rare cancer type Merkle Cell Carcinoma and how Avelumab has changed its treatment paradigm. Once again, it's immunotherapy at its best. So remember, while listening to our podcast, don't forget to wear a hat and apply sunscreen generously!

Links to studies discussed in this episode (subscription may be required):

Migden et al. (Cemiplimab): https://www.nejm.org/doi/10.1056/NEJMoa1805131?url_ver=Z39.88

JAVELIN Merkel 200 (Cohort B): https://jitc.bmj.com/content/9/7/e002646